NCT06871410 2026-01-26Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRoswell Park Cancer InstitutePhase 1 Recruiting26 enrolled
NCT06504459 2025-08-27Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLOHSU Knight Cancer InstitutePhase 2 Recruiting40 enrolled